Takeda Pharmaceutical Co. $TAK Stock Purchased by Quadrant Capital Group LLC

Quadrant Capital Group LLC grew its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 67.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 136,966 shares of the company’s stock after acquiring an additional 55,360 shares during the quarter. Quadrant Capital Group LLC’s holdings in Takeda Pharmaceutical were worth $2,537,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC raised its stake in shares of Takeda Pharmaceutical by 28.8% in the third quarter. Nisa Investment Advisors LLC now owns 2,306 shares of the company’s stock valued at $42,000 after purchasing an additional 515 shares in the last quarter. Focused Alpha LLC lifted its position in Takeda Pharmaceutical by 3.0% in the third quarter. Focused Alpha LLC now owns 19,460 shares of the company’s stock worth $354,000 after purchasing an additional 563 shares during the period. Gold Investment Management Ltd. boosted its stake in Takeda Pharmaceutical by 1.7% during the third quarter. Gold Investment Management Ltd. now owns 107,610 shares of the company’s stock worth $1,957,000 after buying an additional 1,761 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Takeda Pharmaceutical during the third quarter worth $59,000. Finally, Riversedge Advisors LLC acquired a new stake in Takeda Pharmaceutical during the third quarter worth $212,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $19.95 on Thursday. The stock has a market capitalization of $63.94 billion, a price-to-earnings ratio of 58.69 and a beta of -0.07. The business’s fifty day moving average price is $18.51 and its two-hundred day moving average price is $17.30. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $20.13. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.41 by $0.54. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The company had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, analysts predict that Takeda Pharmaceutical Co. will post 1.56 EPS for the current fiscal year.

Insider Activity at Takeda Pharmaceutical

In other news, insider Samaan Farajallah sold 14,006 shares of Takeda Pharmaceutical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $239,502.60. Following the completion of the transaction, the insider owned 116,177 shares in the company, valued at approximately $1,986,626.70. The trade was a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Deidre Greenway sold 12,980 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total value of $235,067.80. Following the completion of the transaction, the insider directly owned 40,049 shares in the company, valued at $725,287.39. The trade was a 24.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 627,457 shares of company stock valued at $10,981,175. Insiders own 0.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on TAK shares. Zacks Research lowered shares of Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 1st. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Weiss Ratings raised shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.